Literature DB >> 1427394

Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrent squamous cancer of the vulva.

A H Russell1, J B Mesic, S A Scudder, P J Rosenberg, L H Smith, W K Kinney, D E Townsend, J D Trelford, M H Taylor, C L Zukowski.   

Abstract

Between July 1987 and September 1991 a program of external beam radiation and synchronous, radiopotentiating chemotherapy was employed to treat 25 women with locoregionally advanced or locoregionally recurrent squamous cancer of the vulva. Of 18 previously untreated patients, 1 was Stage II, 10 were Stage III, 6 were Stage IVA, and 1 was Stage IVB. Reasons for patient referral for nonsurgical management included the presence of initially unresectable disease (5 patients), disease extent which would have necessitated partial or total exenteration if treated surgically (9 patients), disease extent predictive of inadequate surgical margins (less than 1 cm gross margin) if treated by less than exenterative surgery (8 patients), and severe comorbid illness precluding surgical management (3 patients). Complete clinical response was obtained in 16 of 18 previously untreated patients (89%) and in 4 of 7 patients with recurrent disease following vulvar surgery (57%). Of 20 patients achieving a complete clinical response, 3 patients have relapsed within the irradiated volume at 11, 38, and 48 months following completion of treatment. Fourteen patients remain alive and continuously cancer free from 2-52 months after completion of treatment (median follow-up 24 months). This experience suggests that initial management with radiation and chemotherapy may offer some patients with locally advanced squamous cancer of the vulva an alternative to exenterative surgery and may hold curative potential for some patients with surgically unresectable or medically inoperable disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1427394     DOI: 10.1016/0090-8258(92)90068-t

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Neoadjuvant chemoradiotherapy followed by surgery in locally advanced squamous cell carcinoma of the vulva.

Authors:  A Gaudineau; D Weitbruch; P Quetin; S Heymann; T Petit; P Volkmar; F Bodin; M Velten; J F Rodier
Journal:  Oncol Lett       Date:  2012-07-27       Impact factor: 2.967

Review 2.  Carcinoma of the vulva: combined modality treatment.

Authors:  Gustavo S Montana
Journal:  Curr Treat Options Oncol       Date:  2004-04

Review 3.  Chemotherapy of vulvar cancer: a review.

Authors:  Gunter Deppe; Ismail Mert; Jimmy Belotte; Ira S Winer
Journal:  Wien Klin Wochenschr       Date:  2013-03-22       Impact factor: 1.704

Review 4.  Chemoradiation for advanced primary vulval cancer.

Authors:  T S Shylasree; Andrew Bryant; Robert Ej Howells
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

5.  Recommendations for the treatment of vulvar cancer in settings with limited resources: Report from the International Gynecological Cancer Society consensus meeting.

Authors:  Fernando Cotait Maluf; Graziela Dal Molin Zibetti; Eduardo Paulino; Andreia Cristina de Melo; Douglas Racy; Robson Ferrigno; Pedro Luiz Serrano Uson Junior; Reitan Ribeiro; Renato Moretti; Jose Carlos Sadalla; Angelica Nogueira Rodrigues; Filomena Marino Carvalho; Glauco Baiocchi; Donato Callegaro-Filho; Roberto Angioli
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

Review 6.  Recurrent vulvar cancer.

Authors:  Emery M Salom; Manuel Penalver
Journal:  Curr Treat Options Oncol       Date:  2002-04

7.  Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer.

Authors:  Toshiaki Saito; Tsutomu Tabata; Hitoshi Ikushima; Hiroyuki Yanai; Hironori Tashiro; Hitoshi Niikura; Takeo Minaguchi; Toshinari Muramatsu; Tsukasa Baba; Wataru Yamagami; Kazuya Ariyoshi; Kimio Ushijima; Mikio Mikami; Satoru Nagase; Masanori Kaneuchi; Nobuo Yaegashi; Yasuhiro Udagawa; Hidetaka Katabuchi
Journal:  Int J Clin Oncol       Date:  2017-11-20       Impact factor: 3.402

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.